Company intelligence / Profile preview
TrAMPoline Pharma
- Ownership
- Private
- Development stage
- Other
Overview
TrAMPoline Pharma is developing next-generation gene-modified tumor infiltrating lymphocyte therapies. Their lead product MightyTIL™ (TP‑102) has demonstrated superior efficacy in vitro and in vivo compared to conventional unmodified TILs. The company has secured over $15M in funding to support a first-in-human clinical trial expected to begin in early 2026. Additional pipeline programs aim to further enhance TIL function, increase yield/quality prior to harvest, and develop a universal TCR-T cell candidate.
- Therapeutic areas
- Oncology
- Modalities
- Gene-modified cell therapyTumor-infiltrating lymphocyte (TIL) therapyCellular immunotherapy
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on TrAMPoline Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TrAMPoline Pharma.